California state funding advances clinical trials

Thursday, May 5, 2011 01:00 PM

The California Institute for Regenerative Medicine (CIRM) has been awarded taxpayer funding for the first time to study an experimental stem cell treatment on humans, according to The San Diego Union-Tribune.

The $25 million grant went to Calif.-based biopharmaceutical company Geron, which has begun injecting immature versions of special neural cells derived from embryonic stem cells into patients paralyzed by spinal cord injuries.

Geron’s phase I clinical trial is designed to assess the safety and tolerance of GRNOPC1 in humans. The therapy already has been successfully tested in rats.

The company is recruiting participants within 14 days of suffering a spinal cord injury through seven sites around the U.S.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs